Yunyan Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yunyan Shen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Xiaozhong Li
Department of Nephrology and Immunology Children's Hospital of Soochow University Suzhou Jiangsu Province China
2 shared publications - Benshan Zhang
The Affiliated Children’s Hospital of Xiangya School of Medicine, Central South University (Hunan Children’s Hospital) 8 Department of Hematology Changsha
1 shared publication - Chenlu Liu
Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College 1 State Key Laboratory of Common Mechanism Research for Major Diseases Beijing
1 shared publication - Fei Liu
Department of Nephrology, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China
1 shared publication - Haiguo Yu
Department of Rheumatology and Immunology, Children’s Hospital of Nanjing Medical University, Nanjing, China
1 shared publication - Han-Yun Tang
Department of Renal Immunology, Children’s Hospital of Soochow University, Soochow, China
1 shared publication
Latest Publications
- Open Access
- 28 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 3 (1)
Deficiency of NBAS causes immune dysregulation due to hyperactivation of IFN signaling
NBAS deficiency is a multisystem disorder, but its immunologic manifestations and underlying mechanisms remain poorly defined. Here, we expand the genotypic and phenotypic spectrum of NBAS deficiency through four patients carrying five loss-of-function NBAS mutations. Minigene assays and RNA analysis showed that these splicing or missense mutations resulted in aberrant alternative splicing. Clinically, the patients showed early-onset recurrent or persistent cytopenias and immune dysregulation, together with severe infections, inflammatory activation, and multi-organ involvement, including renal and neurologic manifestations. Transcriptomic analysis revealed overactivation of type I interferon signaling pathways compared with healthy controls, and single-cell RNA sequencing demonstrated that this upregulated inflammation was predominantly driven by myeloid cells. Together, these findings identify NBAS deficiency as a cause of immune dysregulation characterized by myeloid-driven type I interferonopathy, expand the clinical spectrum of NBAS-related disorders, and highlight the critical role of NBAS in maintaining immune homeostasis.
- 28 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 3 (1)
Open AccessDeficiency of NBAS causes immune dysregulation due to hyperactivation of IFN signaling
NBAS deficiency is a multisystem disorder, but its immunologic manifestations and underlying mechanisms remain poorly defined. Here, we expand the genotypic and phenotypic spectrum of NBAS deficiency through four patients carrying five loss-of-function NBAS mutations. Minigene assays and RNA analysis showed that these splicing or missense mutations resulted in aberrant alternative splicing. Clinically, the patients showed early-onset recurrent or persistent cytopenias and immune dysregulation, together with severe infections, inflammatory activation, and multi-organ involvement, including renal and neurologic manifestations. Transcriptomic analysis revealed overactivation of type I interferon signaling pathways compared with healthy controls, and single-cell RNA sequencing demonstrated that this upregulated inflammation was predominantly driven by myeloid cells. Together, these findings identify NBAS deficiency as a cause of immune dysregulation characterized by myeloid-driven type I interferonopathy, expand the clinical spectrum of NBAS-related disorders, and highlight the critical role of NBAS in maintaining immune homeostasis.
- Open Access
- 1 January 2024
- Published by Wiley in Journal of Immunology Research
- Vol. 2024 (1) , 5722548
Clinical and Genetic Spectrum of Nine Cases of NLRP3‐Associated Autoinflammatory Disease (NLRP3‐AID) and Identification of One Novel NLRP3 Mutation by Genetic Variation Analyses
Purpose. NLRP3‐associated autoinflammatory disease (NLRP3‐AID) is characterized by gain‐of‐function variants in the NLRP3 gene. Since there are little literature focusing on pediatric NLRP3‐AID in China, we aimed to elucidate the phenotypic and genotypic profiles of Chinese patients with NLRP3‐AID. Methods. Patients with NLRP3‐AID at three rheumatology centers in China were genotyped through whole exome sequencing or gene panel sequencing. Sanger sequencing was performed on all patients and their parents. Clinical phenotype, treatment, and prognosis were analyzed. Results. Nine patients with NLRP3‐AID were enrolled between December 2014 and October 2022 with an average follow‐up period exceeding 30 months. The median age of onset was 12 months, and 66.7% were younger than 3 years old. The diagnosis was significantly delayed and the median delay duration was 115 months. The patients most commonly presented with rash (100%), arthritis/arthralgia (88.9%), lymphadenopathy (88.9%), fever (77.8%), and growth retardation (44.4%). During acute attack, white blood cell, C‐reactive protein, and/or erythrocyte sedimentation rate all increased in all cases, and inflammatory markers remained elevated beyond 7 days postfever resolution in 57.1% of patients (4/7). Two cases of chronic infantile neurological cutaneous articular syndrome (CINCA) had clubbed fingers, one with interstitial lung disease, a finding rarely reported. Treatment with glucocorticoids (77.8%) and biologic agents (33.3%) yielded 66% complete remission and 33% partial remission. Genetic analysis identified eight pathogenic NLRP3 missense mutations, including one novel mutation. Conclusions. Our study illuminated the distinct clinical and genetic features of Chinese NLRP3‐AID patients, emphasizing the significance of early genetic screening. Despite delayed diagnosis, treatment primarily with glucocorticoids and biologic agents, led to favorable outcomes. Genetic heterogeneity, including a novel mutation, highlighted the complexity of NLRP3‐AID in this population.
- 1 January 2024
- Published by Wiley in Journal of Immunology Research
- Vol. 2024 (1) , 5722548
Open AccessClinical and Genetic Spectrum of Nine Cases of NLRP3‐Associated Autoinflammatory Disease (NLRP3‐AID) and Identification of One Novel NLRP3 Mutation by Genetic Variation Analyses
Purpose. NLRP3‐associated autoinflammatory disease (NLRP3‐AID) is characterized by gain‐of‐function variants in the NLRP3 gene. Since there are little literature focusing on pediatric NLRP3‐AID in China, we aimed to elucidate the phenotypic and genotypic profiles of Chinese patients with NLRP3‐AID. Methods. Patients with NLRP3‐AID at three rheumatology centers in China were genotyped through whole exome sequencing or gene panel sequencing. Sanger sequencing was performed on all patients and their parents. Clinical phenotype, treatment, and prognosis were analyzed. Results. Nine patients with NLRP3‐AID were enrolled between December 2014 and October 2022 with an average follow‐up period exceeding 30 months. The median age of onset was 12 months, and 66.7% were younger than 3 years old. The diagnosis was significantly delayed and the median delay duration was 115 months. The patients most commonly presented with rash (100%), arthritis/arthralgia (88.9%), lymphadenopathy (88.9%), fever (77.8%), and growth retardation (44.4%). During acute attack, white blood cell, C‐reactive protein, and/or erythrocyte sedimentation rate all increased in all cases, and inflammatory markers remained elevated beyond 7 days postfever resolution in 57.1% of patients (4/7). Two cases of chronic infantile neurological cutaneous articular syndrome (CINCA) had clubbed fingers, one with interstitial lung disease, a finding rarely reported. Treatment with glucocorticoids (77.8%) and biologic agents (33.3%) yielded 66% complete remission and 33% partial remission. Genetic analysis identified eight pathogenic NLRP3 missense mutations, including one novel mutation. Conclusions. Our study illuminated the distinct clinical and genetic features of Chinese NLRP3‐AID patients, emphasizing the significance of early genetic screening. Despite delayed diagnosis, treatment primarily with glucocorticoids and biologic agents, led to favorable outcomes. Genetic heterogeneity, including a novel mutation, highlighted the complexity of NLRP3‐AID in this population.
- Open Access
- 3 August 2019
- Published by Springer Nature in Rheumatology International
- Vol. 40 (5) , 811-819
Acute pancreatitis and macrophage activation syndrome in pediatric systemic lupus erythematosus: case-based review
Pancreatitis is uncommon in systemic lupus erythematosus (SLE) and is rarely reported in children, possibly being related to macrophage activation syndrome (MAS). The incidence of MAS in children with lupus pancreatitis is unknown, as is their prognosis. In this case-based review, we report a pediatric patient with SLE complicated with pancreatitis and MAS, and performed a literature review. We report an 11-year-old girl with SLE and MAS who developed pancreatitis on the second day of methylprednisolone pulse therapy (500 mg/day). We continued methylprednisolone pulse therapy, and performed three rounds of DNA-immunoadsorption and three rounds of hemoperfusion. A second course of methylprednisolone pulse therapy was initiated 9 days later. The patient received a monthly cyclophosphamide pulse therapy (10 mg/kg/day, 2 consecutive days every month) for 6 months, after which she was treated with mycophenolate mofetil 20 mg/kg/day. The condition of the patient gradually improved, her blood amylase and lipase decreased. She was in a stable condition during 13-month follow-up period. Review of the literature of pediatric patients with SLE and pancreatitis showed that there are 127 cases that have been reported in the past 30 years, 40 cases were excluded in our study because of inadequate information. Of the 87 patients included in our literature review, the mortality rate was 33.33%, and 52.86% of the patients with pancreatitis had MAS at the same time. Pancreatitis is uncommon in SLE, but must be suspected if a patient with SLE develops digestive symptoms. Patients with SLE with pancreatitis have a high incidence of MAS and high mortality rate; however, early recognition and effective treatment can relieve the disease symptoms.
- 3 August 2019
- Published by Springer Nature in Rheumatology International
- Vol. 40 (5) , 811-819
Open AccessAcute pancreatitis and macrophage activation syndrome in pediatric systemic lupus erythematosus: case-based review
Pancreatitis is uncommon in systemic lupus erythematosus (SLE) and is rarely reported in children, possibly being related to macrophage activation syndrome (MAS). The incidence of MAS in children with lupus pancreatitis is unknown, as is their prognosis. In this case-based review, we report a pediatric patient with SLE complicated with pancreatitis and MAS, and performed a literature review. We report an 11-year-old girl with SLE and MAS who developed pancreatitis on the second day of methylprednisolone pulse therapy (500 mg/day). We continued methylprednisolone pulse therapy, and performed three rounds of DNA-immunoadsorption and three rounds of hemoperfusion. A second course of methylprednisolone pulse therapy was initiated 9 days later. The patient received a monthly cyclophosphamide pulse therapy (10 mg/kg/day, 2 consecutive days every month) for 6 months, after which she was treated with mycophenolate mofetil 20 mg/kg/day. The condition of the patient gradually improved, her blood amylase and lipase decreased. She was in a stable condition during 13-month follow-up period. Review of the literature of pediatric patients with SLE and pancreatitis showed that there are 127 cases that have been reported in the past 30 years, 40 cases were excluded in our study because of inadequate information. Of the 87 patients included in our literature review, the mortality rate was 33.33%, and 52.86% of the patients with pancreatitis had MAS at the same time. Pancreatitis is uncommon in SLE, but must be suspected if a patient with SLE develops digestive symptoms. Patients with SLE with pancreatitis have a high incidence of MAS and high mortality rate; however, early recognition and effective treatment can relieve the disease symptoms.